COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

121.70

Increased from previous period

Positive OCF/share while Healthcare median is negative. Peter Lynch might see a key advantage in a struggling sector.

Free Cash Flow per Share

121.70

Increased from previous period

Positive FCF/share while Healthcare median is negative. Peter Lynch might see a strong edge over peers.

Capex-to-Operating Cash Flow

No Data

No Data available this quarter, please select a different quarter.

Income Quality Ratio (OCF / Net Income)

1.90

Increased from previous period

Ratio above 1.5x Healthcare median of 0.79. Joel Greenblatt would see if robust OCF is a recurring trait.

Operating Cash Flow-to-Sales Ratio

4.11%

Increased from previous period

OCF-to-sales ratio of 4.11% while Healthcare is zero. Walter Schloss might see a modest advantage in actually generating some cash.

Select Chart Metric:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

121.70

Increased from previous period

Positive OCF/share while Healthcare median is negative. Peter Lynch might see a key advantage in a struggling sector.

Free Cash Flow per Share

121.70

Increased from previous period

Positive FCF/share while Healthcare median is negative. Peter Lynch might see a strong edge over peers.

Capex-to-Operating Cash Flow

No Data

No Data available this quarter, please select a different quarter.

Income Quality Ratio (OCF / Net Income)

1.90

Increased from previous period

Ratio above 1.5x Healthcare median of 0.79. Joel Greenblatt would see if robust OCF is a recurring trait.

Operating Cash Flow-to-Sales Ratio

4.11%

Increased from previous period

OCF-to-sales ratio of 4.11% while Healthcare is zero. Walter Schloss might see a modest advantage in actually generating some cash.

Select Chart Metric: